Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the American College of Cardiology (ACC) have launched a new journal named JACC: Heart Failure. This journal will better meet the demands and challenges of treating what is now the most rapidly increasing category of cardiac disease. The first publication is now available here.
Christopher O'Connor, MD, FACC will serve as editor-in-chief of JACC: Heart Failure. Each bi-monthly issue will present high-quality content, authored by experts worldwide, with a unique focus on new research and treatment options. The journal intends to improve the understanding of the disease, clinical trials, clinical outcomes and advances in therapies through scientific communication.
A state-of-the-condition update by Dr. Eugene Braunwald and the breadth of articles featured in the first issue are an example of the journal's aims to publish the full range of topics related to this condition—including basic and translational science, trials and registries, co-morbidities, biomarkers, advanced heart failure and outcomes.
"The addition of JACC: Heart Failure to ACC's current portfolio will help meet the need for more research in this growing field," said William Zoghbi, MD, FACC, president of ACC. "With the increasing rate of patients suffering from heart failure, the science presented in this new journal will give cardiologists access to valuable new research."
Cynthia Baudendistel, executive publisher for the ACC journals, Elsevier, added, "We are delighted to be publishing JACC: Heart Failure in collaboration with the ACC. We look forward to seeing the impact this journal will make on cardiology practice, research, teaching, and advocacy."